Prion protein amyloidosis

Bernardino Ghetti, Pedro Piccardo, Blas Frangione, Orso Bugiani, Giorgio Giaccone, Katherine Young, Frances Prelli, Martin Farlow, Stephen Dlouhy, Fabrizio Tagliavini

Research output: Contribution to journalArticle

157 Citations (Scopus)

Abstract

The prion protein (PrP) plays an essential role in the pathogenesis of a group of sporadic, genetically determined and infectious fatal degenerative diseases, referred to as 'prion diseases', affecting the central nervous system of humans and other mammals. The cellular PrP is encoded by a single copy gene, highly conserved across mammalian species. In prion diseases, PrP undergoes conformational changes involving a shift from α-helix to β-sheet structure. This conversion is important for PrP amyloidogenesis, which occurs to the highest degree in the genetically determined Gerstmann-Straussler-Scheinker disease (GSS) and prion protein cerebral amyloid angiopathy (PrP-CAA), while it is less frequently seen in other prion diseases. GSS and PrP-CAA are associated with point mutations of the prion protein gene (PRNP); these conditions show a broad spectrum of clinical presentation, the main signs being ataxia, spastic paraparesis, extrapyramidal signs and dementia. In GSS, parenchymal amyloid may be associated with spongiform changes or neurofibrillary lesions; in PrP-CAA, vascular amyloid is associated with neurofibrillary lesions. A major component of the amyloid fibrils in the two diseases is a 7 kDa peptide, spanning residues 81-150 of PrP.

Original languageEnglish
Pages (from-to)127-145
Number of pages19
JournalBrain Pathology
Volume6
Issue number2
StatePublished - Apr 1996

Fingerprint

Amyloidosis
Gerstmann-Straussler-Scheinker Disease
Prion Diseases
Amyloid
Spastic Paraparesis
Cerebral Amyloid Angiopathy
Prion Proteins
Ataxia
Point Mutation
Genes
Blood Vessels
Dementia
Mammals
Central Nervous System
Peptides

ASJC Scopus subject areas

  • Neuroscience(all)
  • Pathology and Forensic Medicine

Cite this

Ghetti, B., Piccardo, P., Frangione, B., Bugiani, O., Giaccone, G., Young, K., ... Tagliavini, F. (1996). Prion protein amyloidosis. Brain Pathology, 6(2), 127-145.

Prion protein amyloidosis. / Ghetti, Bernardino; Piccardo, Pedro; Frangione, Blas; Bugiani, Orso; Giaccone, Giorgio; Young, Katherine; Prelli, Frances; Farlow, Martin; Dlouhy, Stephen; Tagliavini, Fabrizio.

In: Brain Pathology, Vol. 6, No. 2, 04.1996, p. 127-145.

Research output: Contribution to journalArticle

Ghetti, B, Piccardo, P, Frangione, B, Bugiani, O, Giaccone, G, Young, K, Prelli, F, Farlow, M, Dlouhy, S & Tagliavini, F 1996, 'Prion protein amyloidosis', Brain Pathology, vol. 6, no. 2, pp. 127-145.
Ghetti B, Piccardo P, Frangione B, Bugiani O, Giaccone G, Young K et al. Prion protein amyloidosis. Brain Pathology. 1996 Apr;6(2):127-145.
Ghetti, Bernardino ; Piccardo, Pedro ; Frangione, Blas ; Bugiani, Orso ; Giaccone, Giorgio ; Young, Katherine ; Prelli, Frances ; Farlow, Martin ; Dlouhy, Stephen ; Tagliavini, Fabrizio. / Prion protein amyloidosis. In: Brain Pathology. 1996 ; Vol. 6, No. 2. pp. 127-145.
@article{18739bae1e5d4bba9d6354b70454c84b,
title = "Prion protein amyloidosis",
abstract = "The prion protein (PrP) plays an essential role in the pathogenesis of a group of sporadic, genetically determined and infectious fatal degenerative diseases, referred to as 'prion diseases', affecting the central nervous system of humans and other mammals. The cellular PrP is encoded by a single copy gene, highly conserved across mammalian species. In prion diseases, PrP undergoes conformational changes involving a shift from α-helix to β-sheet structure. This conversion is important for PrP amyloidogenesis, which occurs to the highest degree in the genetically determined Gerstmann-Straussler-Scheinker disease (GSS) and prion protein cerebral amyloid angiopathy (PrP-CAA), while it is less frequently seen in other prion diseases. GSS and PrP-CAA are associated with point mutations of the prion protein gene (PRNP); these conditions show a broad spectrum of clinical presentation, the main signs being ataxia, spastic paraparesis, extrapyramidal signs and dementia. In GSS, parenchymal amyloid may be associated with spongiform changes or neurofibrillary lesions; in PrP-CAA, vascular amyloid is associated with neurofibrillary lesions. A major component of the amyloid fibrils in the two diseases is a 7 kDa peptide, spanning residues 81-150 of PrP.",
author = "Bernardino Ghetti and Pedro Piccardo and Blas Frangione and Orso Bugiani and Giorgio Giaccone and Katherine Young and Frances Prelli and Martin Farlow and Stephen Dlouhy and Fabrizio Tagliavini",
year = "1996",
month = "4",
language = "English",
volume = "6",
pages = "127--145",
journal = "Brain Pathology",
issn = "1015-6305",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Prion protein amyloidosis

AU - Ghetti, Bernardino

AU - Piccardo, Pedro

AU - Frangione, Blas

AU - Bugiani, Orso

AU - Giaccone, Giorgio

AU - Young, Katherine

AU - Prelli, Frances

AU - Farlow, Martin

AU - Dlouhy, Stephen

AU - Tagliavini, Fabrizio

PY - 1996/4

Y1 - 1996/4

N2 - The prion protein (PrP) plays an essential role in the pathogenesis of a group of sporadic, genetically determined and infectious fatal degenerative diseases, referred to as 'prion diseases', affecting the central nervous system of humans and other mammals. The cellular PrP is encoded by a single copy gene, highly conserved across mammalian species. In prion diseases, PrP undergoes conformational changes involving a shift from α-helix to β-sheet structure. This conversion is important for PrP amyloidogenesis, which occurs to the highest degree in the genetically determined Gerstmann-Straussler-Scheinker disease (GSS) and prion protein cerebral amyloid angiopathy (PrP-CAA), while it is less frequently seen in other prion diseases. GSS and PrP-CAA are associated with point mutations of the prion protein gene (PRNP); these conditions show a broad spectrum of clinical presentation, the main signs being ataxia, spastic paraparesis, extrapyramidal signs and dementia. In GSS, parenchymal amyloid may be associated with spongiform changes or neurofibrillary lesions; in PrP-CAA, vascular amyloid is associated with neurofibrillary lesions. A major component of the amyloid fibrils in the two diseases is a 7 kDa peptide, spanning residues 81-150 of PrP.

AB - The prion protein (PrP) plays an essential role in the pathogenesis of a group of sporadic, genetically determined and infectious fatal degenerative diseases, referred to as 'prion diseases', affecting the central nervous system of humans and other mammals. The cellular PrP is encoded by a single copy gene, highly conserved across mammalian species. In prion diseases, PrP undergoes conformational changes involving a shift from α-helix to β-sheet structure. This conversion is important for PrP amyloidogenesis, which occurs to the highest degree in the genetically determined Gerstmann-Straussler-Scheinker disease (GSS) and prion protein cerebral amyloid angiopathy (PrP-CAA), while it is less frequently seen in other prion diseases. GSS and PrP-CAA are associated with point mutations of the prion protein gene (PRNP); these conditions show a broad spectrum of clinical presentation, the main signs being ataxia, spastic paraparesis, extrapyramidal signs and dementia. In GSS, parenchymal amyloid may be associated with spongiform changes or neurofibrillary lesions; in PrP-CAA, vascular amyloid is associated with neurofibrillary lesions. A major component of the amyloid fibrils in the two diseases is a 7 kDa peptide, spanning residues 81-150 of PrP.

UR - http://www.scopus.com/inward/record.url?scp=15844415943&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15844415943&partnerID=8YFLogxK

M3 - Article

C2 - 8737929

AN - SCOPUS:15844415943

VL - 6

SP - 127

EP - 145

JO - Brain Pathology

JF - Brain Pathology

SN - 1015-6305

IS - 2

ER -